1. Subcutaneous Olanzapine for Hyperactive or Mixed Delirium in Patients with Advanced Cancer: A Preliminary Study 
Ahmed Elsayem, MD, Shirley H. Bush, MBBS, Mark F. Munsell, MD, Eardie Curry, MD, Bianca B. Calderon, PharmD, Timotheos Paraskevopoulos, RN, Nada Fadul, MD, Eduardo Bruera, MD 
Journal of Pain and Symptom Management 
Volume 40, Issue 5, Pages (November 2010)
DOI: /j.jpainsymman
Copyright © 2010 U.S. Cancer Pain Relief Committee Terms and Conditions

2. Fig. 1
The 24-hour total parenteral haloperidol doses before study (baseline) and final 24 hours on study.
Journal of Pain and Symptom Management  , DOI: ( /j.jpainsymman )
Copyright © 2010 U.S. Cancer Pain Relief Committee Terms and Conditions

3. Fig. 2
RASS scores before study at baseline (Time 0) and at completion of study.
Journal of Pain and Symptom Management  , DOI: ( /j.jpainsymman )
Copyright © 2010 U.S. Cancer Pain Relief Committee Terms and Conditions